Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social)

N/A

Report date: 2022/11/20 16:16:22

Base Information

Drug NameEquine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionAnti-Coronavirus spike glycoprotein
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCosta Rica
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversidad De Costa Rica
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversidad De Costa Rica
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A